Moreover, the results obtained in our models with Sunitinib and with dominant negative PDGFRA suggest that therapeutics approaches leading to complete inhibition of PDGFRA signaling can be highly efficacious in KS treatment. Here, PDGFRA is linked to Kaposi's sarcoma.